Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

<p>Extended Data relating to Main Figure 4/Targeting of AKT-driven subclonal progression of ALDH1A1+ cells. A, Collected source data for main Figs. 4B,C,F-H. Left, diagrams: in vitro cell confluence dynamics of paired treatment naive vs. TMZ-related experimental (TMZ→eR; BN46) or clinical (RT/...

Saved in:

書目詳細資料
主要作者:	Sied Kebir (15048732) (author)
其他作者:	Vivien Ullrich (15048735) (author), Pia Berger (15048738) (author), Celia Dobersalske (15048741) (author), Sarah Langer (15048744) (author), Laurèl Rauschenbach (15048747) (author), Daniel Trageser (15048750) (author), Andreas Till (15048753) (author), Franziska K. Lorbeer (15048756) (author), Anja Wieland (15048759) (author), Timo Wilhelm-Buchstab (15048762) (author), Ashar Ahmad (15048765) (author), Holger Fröhlich (8724576) (author), Igor Cima (15048768) (author), Shruthi Prasad (15048771) (author), Johann Matschke (15048774) (author), Verena Jendrossek (15048777) (author), Marc Remke (14962619) (author), Barbara M. Grüner (14947089) (author), Alexander Roesch (15048780) (author), Jens T. Siveke (11780911) (author), Christel Herold-Mende (15047946) (author), Tobias Blau (15048783) (author), Kathy Keyvani (15048786) (author), Frank K.H. van Landeghem (15048789) (author), Torsten Pietsch (15048792) (author), Jörg Felsberg (15048795) (author), Guido Reifenberger (12335398) (author), Michael Weller (15037908) (author), Ulrich Sure (15048798) (author), Oliver Brüstle (15048801) (author), Matthias Simon (15048804) (author), Martin Glas (15048807) (author), Björn Scheffler (15048810) (author)
出版:	2025
主題:	Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure 1 from Current Status and Challenges of Vaccination Therapy for Glioblastoma
由: Hamed Hosseinalizadeh (15062761)
出版: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
由: Tobias Kessler (17079209)
出版: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
由: Bachchu Lal (17141949)
出版: (2025)

Supplementary Figure S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Table S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
由: Fleur M.G. Cornelissen (22761190)
出版: (2025)

Supplementary Figure S1 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
由: Humeyra Kaanoglu (21903844)
出版: (2025)

Supplementary Figure S2 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
由: Humeyra Kaanoglu (21903844)
出版: (2025)

Supplementary Figure S3 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
由: Humeyra Kaanoglu (21903844)
出版: (2025)

Supplementary Figure S4 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
由: Humeyra Kaanoglu (21903844)
出版: (2025)

Supplementary Figure S5 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
由: Humeyra Kaanoglu (21903844)
出版: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
由: Defne Bayik (14961098)
出版: (2025)